Notes
Comparative Effectiveness Public Advisory Council
Reference
Institute for Clinical and Economic Review. ICER Releases Draft Evidence Report Reviewing Olaparib, Rucaparib, and Niraparib for Ovarian Cancer. Internet Document : 12 Jul 2017. Available from: URL: https://icer-review.org/announcements/ovarian-draft-report/
Rights and permissions
About this article
Cite this article
ICER draft report on PARP inhibitors for ovarian cancer. PharmacoEcon Outcomes News 783, 3 (2017). https://doi.org/10.1007/s40274-017-4174-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4174-6